With a multi-cyclin-dependent kinase (CDK) small-molecule inhibitor working its way toward phase III trials next year in acute myeloid leukemia (AML), Tolero Pharmaceuticals Inc. raised $14.2 million in series B money that will also help advance the Salt Lake City-based firm's significant preclinical pipeline.